An interventional study of Semaglutide Oral Tablet and Placebo in Chronic Kidney Diseases and MAFLD, sponsored by Institute of Liver and Biliary Sciences, India. Recruiting at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing semaglutide in Renal Insufficiency, Chronic — 9 open to participants now, 9 under way, 1 of them phase 3. Semaglutide · Renal Insufficiency, Chronic.
Among the 14 studies testing semaglutide in Renal Insufficiency, Chronic, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 with no phase, and was the 10th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →9 of the 14 studies testing semaglutide in Renal Insufficiency, Chronic are open now, in 9 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Western University, Canada · Sites in Canada
Ages 18+
The George Institute · Sites in Australia, India, New Zealand and 2 more countries
Ages 18+
Srinvasan Beddhu · Sites in United States
Ages 20+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 77 across the 14 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Institute of Liver and Biliary Sciences, India is the lead sponsor of 303 studies on the registry; 87 are open to participants now.
Institute of Liver and Biliary Sciences, India has 2 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
2 of the studies testing semaglutide in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
| NCT07017270Unity Health TorontoGlucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing semaglutide in Renal Insufficiency, Chronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can slow or prevent this progression.
NAFLD and CKD frequently coexist due to shared mechanisms such as insulin resistance, inflammation, oxidative stress, dyslipidemia, and metabolic syndrome. Because of these overlapping pathways, a single therapy targeting both organs may offer major benefits.
Semaglutide is known to reduce liver fat, improve inflammation and fibrosis, promote weight loss, and provide renal protection. This project will test whether adding oral semaglutide to standard care leads to better kidney and liver outcomes than standard care alone.
The study is designed as a randomised controlled trial conducted at ILBS, enrolling adults having NAFLD with CKD (with specific eGFR and albuminuria criteria). Participants will be followed for 2 years, with regular assessment of kidney function (eGFR, ACR), liver health (FibroScan, ALT/AST), metabolic parameters, and cardiovascular outcomes.
A parallel animal study in mice with diet-induced fatty liver disease will validate mechanistic findings through liver and kidney histology, gene expression, metabolic tests, and biochemical markers after semaglutide treatment.
Expected outcome: To demonstrate that semaglutide slows CKD progression and improves NAFLD, supporting its use as a therapeutic option for patients with coexisting both conditions.
NAFLD and metabolic syndrome have emerged as significant health concerns globally, with substantial implications for kidney health.The interplay between NAFLD, metabolic syndrome, and CKD necessitates a comprehensive understanding of the underlying mechanisms and shared pathogenic pathways. Their shared risk factors, molecular mechanisms, and genetic predisposition represent the basis for this relationship.
Accordingly, treatment approaches with combined efficacy in NAFLD and chronic renal impairment are expected to positively impact the natural history of this deleterious interaction.
GLP1-R agonists GLP1-R agonists (GLP1-RAs) are novel potent antidiabetic agents with proven efficacy in reducing major adverse cardiovascular events. Besides their glucose-lowering action, their beneficial hepatic effects may be related to the influence on the AMPK/mTOR pathway. Semaglutide was associated with significant decreases in body weight, alanine aminotransferase, liver steatosis, and stiffness.GLP1-RAs may also improve histologic features on NAFLD, such as liver fat deposition, steatohepatitis, and fibrosis. GLP1-RAs have shown benefits in preventing the development or halting the progression of CKD. It also promotes antioxidative and anti-inflammatory actions may be among the determining factors in this renoprotective effect, together with weight loss, blood pressure, and glucose-lowering.
Primary objective-To measure the progression of CKD and NAFLD in Semaglutide treated group versus non treated group.
Secondary objectives-1.To conduct animal model studies to confirm the primary objective by performing the liver and renal histology.
Study Population-All patients diagnosed to have NAFLD with or without DM Type2 with CKD(GFR\<60 ML/MIN AND ALBUMINURIA (>330 MG/MMOL)will be included in the study.
STUDY PLAN Type of study-Randomised Control Trial(RCT) Study period-3 years Intervention-adding oral semaglutide once a day (starting from 3mg to 14 mg ).we will start from 3mg once a day and go upto 14 mg once a day . Control arm-patients receiving standard of care.
Statistical analysis: Categorical values were reported as numbers, frequencies and percentages. Continuous data was reported as median and interquartile range (IQR) or mean with standard deviation. Chi square/Chi square with yate's correction/Fisher test was used for comparing categorical values depending on the sample size. For comparing continuous data, unpaired t-test or Mann Whitney was used as appropriate16 was used for statistical analysis. A p-value of below 0.05 was adapted as a value of statistical significance for the purpose of this study.Intension to treat and per protocol analysis will be done and any adverse event will be reported.
ANIMAL MODEL Male C57BL/6J mice (6 weeks old) are selected for the study Mice will be induced to liver disease by feeding a rodent diet with 58 Kcal% fat and sucrose (D12331- Research diets) for 20- 32 weeks and Mice on a standard chow diet will be included as controls. 6-week-old mice will be fed with 50% supplementation of a High-fat diet with standard chow diet for acclimatization for period of two weeks. Post which a complete high fat diet will be administered.
To reflect the disease state at the start of treatment, animals will be sacrificed from both groups. Histology for liver and kidney will be performed at dose start (baseline group), other endpoints and biochemical parameters will also be analyzed at this point.
Oral animal equivalent dose will be calculated using known human dose of Semaglutide. Oral semaglutide pills will be crushed into powder form and resuspended in distilled water for oral gavage. Semaglutide or vehicle (Distilled water/ Normal saline) will be administered orally daily for 8-12 weeks, while body weight, food and water consumption will be monitored daily. Weekly Insulin tolerance test and glucose tolerance test will be performed from the start of 20th weeks to analyze insulin resistance and hyperglycemia in mice model.
At study termination, blood sampled via retro-orbital will be collected for analysis of liver enzymes, plasma lipids (ALT, AST, TG and TC), serum urea, creatinine, and blood urea nitrogen. Urine will be collected to measure Albumin and creatinine using commercially available ELISA kits. Collected plasma samples will be used to measure levels of Adiponectin, leptin, resistin and ghrelin using commercially available ELISA kits. Animals will be euthanized using ketamine and xylazine cocktail, and liver and renal tissues will be collected weighed and subjected to histology, gene expression and other biochemical parameters for further study and inference.
These expected deliverable aim to demonstrate the efficacy of Semaglutide in slowing the progression of CKD and NAFLD, validated through both clinical and preclinical studies, thereby supporting its potential use as a therapeutic option for these conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current (or within 90 days) chronic or intermittent haemodialysis or peritoneal dialysis 13 Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupildilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control arm : Participants in this arm will receive Placebo with Standard Medical Treatment (SMT).
Other: Placebo · Other: Standard medical treatment
Semaglutide with Standard Medical Treatment: Participants in this arm will receive Standard medical treatment and oral semaglutide starting from 3mg dose daily that gradually increases upto 14mg dose daily for 6 months.
Drug: Semaglutide Oral Tablet · Other: Standard medical treatment
GLP1-R agonists GLP1-R agonists (GLP1-RAs) are novel potent antidiabetic agents with proven efficacy in reducing major adverse cardiovascular events. Besides their glucose-lowering action, their beneficial hepatic effects may be related to the influence on the AMPK/mTOR pathway. Semaglutide was associated with significant decreases in body weight, alanine aminotransferase, liver steatosis, and stiffness.GLP1-RAs may also improve histologic features on NAFLD, such as liver fat deposition, steatohepatitis, and fibrosis. GLP1-RAs have shown benefits in preventing the development or halting the progression of CKD. It also promotes antioxidative and anti-inflammatory actions may be among the determining factors in this renoprotective effect, together with weight loss, blood pressure, and glucose-lowering.
Placebo will be given in the same manner.
Standard medical treatment- 1. Lifestyle first - weight loss , caloric restriction, increased aerobic + resistance exercise, treat obesity and metabolic syndrome. 2. Optimize blood-pressure control and use RAAS blockade when indicated (ACE inhibitor or ARB) to reduce albuminuria and slow CKD progression . 3. Treat dysglycaemia and favour drug classes with kidney + liver benefit when appropriate * SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD * GLP-1 receptor agonists (e.g., semaglutide) 4. Lipid management / statins - treat according to CV risk 5. Consider established liver-directed agents when appropriate 6. Pioglitazone (thiazolidinedione) and vitamin-E 7. Standard CKD supportive care - salt and fluid management, correction of metabolic acidosis, anaemia and mineral bone abnormalities as per CKD stage; immunize and address CV risk factors aggressively 8. Avoid hepatotoxic drugs / review medications
Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease.
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Annual rate of change in eGFR (chronic kidney disease - epidemiology collaboration (CKD-EPI))
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
ime to first occurrence of a composite cardiovascular major adverse cardiovascular event (MACE) endpoint consisting of: Non-fatal myocardial infarction, non-fatal stroke, and cardiovascular (CV) death
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Time to occurrence of all-cause death
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in eGFR and proteinuria.
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Annual rate of change in eGFR (CKD-EPI) (chronic eGFR slope)
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in eGFR (CKD-EPI) and cystatin C
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in albumin creatinine ratio(ACR)
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in bodyweight
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in HBA1c
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in Systolic and diastolic BP
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Number of hypoglycemic episodes
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Changes in the liver histology in the animal model as assessed by Alpha-SMA, Col-1.
Time frame: 4,8,16,24 weeks
Changes in the liver histology in the animal model as assessed by SGOT/SGPT.
Time frame: 4,8,16,24 weeks
Changes in the renal histology in the animal model as assessed by UPCR,GFR,Creatinine clearance.
Time frame: 4,8,16,24 weeks
Changes in the renal histology in the animal model as assessed by FITC-Sinistrin Clearance,cystatin-C.
Time frame: 4,8,16,24 weeks
Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Changes in liver stiffness values assessed by transient elastography (FibroScan®)
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in ELF (Enhanced Liver Fibrosis) score
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in ALT/AST
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in CAP (Controlled Attenuation Parameter) values assessed by transient elastography (FibroScan)
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in FAST (FibroScan-AST) score
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in inflammation assessed by hsCRP (High Sensitive C-Reactive Protein)
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Change in triglyceride/LDL
Time frame: 3 months, 6 months, 12 months,18 months and 24 months
Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 31 months is above that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → May 2026, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Renal Insufficiency, Chronic →
Institute of Liver and Biliary Sciences, India →